Colorectal cancer (CRC) is the third most common cancer diagnosed in the United States. Unfortunately, up to 20% of new CRC cases have metastases at the time of diagnosis. The most common sites of metastatic disease in CRC are the liver, lung, and peritoneum. Close to 5% of patients with CRC will present with peritoneal carcinomatosis (PC). One of the many challenges of treating PC in stage IV CRC patients is drug delivery. It is often difficult to attain adequate drug levels within the peritoneum. If chemotherapy doses are subsequently increased in attempts to raise drug concentrations, the patient is exposed to more systemic side effects. HIPEC aims to deliver chemotherapy directly to the peritoneum, which can increase local drug concentrations, as well as reduce the total systemic exposure from the chemotherapy. CRS and HIPEC do appear to have promising data when used in the optimal patient population. It is important, when considering CRS and HIPEC, that a patient reviews an institution’s experience with this collaborative treatment approach.
Search Surgeon by State
HIPEC Colon Cancer Patients Share Their Stories
Young UK Researcher Fights Back
LEXINGTON, Ky. (June 24,...
Susan Mays’ Story
Susan Mays, of Du Quoin, noticed some subtle changes in her regular bathroom habits in spring 2019, so she called her primary care physician. She saw Kathy Laird, nurse practitioner, who expressed concern and started running tests.
Nurse helps mother find rare cancer treatment
Last summer, 72-year-old Robert Bochat was carrying a heavy piece of furniture out of his house when…
“It is an amazing surgery that unfortunately not many doctors and hospitals are even are aware of. I recommend MD Anderson and Dr. Keith Fournier without hesitation.”
The Heat that Healed
With his abdomen covered in...